For Allergan Suitors, Unorthodox Alliance Proved Unwieldy

A look at the partnership of Valeant CEO Michael Pearson and activist investor William Ackman in their failed $53 billion bid to acquire Allergan shows that the two men didn’t always see eye to eye.



from WSJ.com: US Business http://ift.tt/1uyWsUr

via IFTTT